Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Laughing gas may not mess with Kids' lung germs

NCT ID NCT07118644

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether using a gas called MEOPA (laughing gas) to calm children during a lung sample procedure changes the types of bacteria found in their airways. 23 children aged 3 months to 8 years old took part. The goal was to see if the gas affects the accuracy of the bacteria test results.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MEOPA (a gas with pain-relieving and anxiety-reducing properties, also known as laughing gas)
What this could lead to
If it works, this could show that using MEOPA does not interfere with lung bacteria samples, making the procedure more comfortable for children without affecting test results.
What could go wrong
This is a very small study (23 children) looking only at short-term changes in bacteria, not at health outcomes. The results may not apply to all children or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

23 people

The number who actually took part.

Started

Sep 2025

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

3 months to 8 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Children aged from 3 months to 8 years old * Patients requiring ECBC in routine practice: acute respiratory distress with suspected bacterial respiratory infection (superinfected bronchiolitis or asthma attack, suspected pneumonia) and severe asthma assessment * Child unable to expectorate effectively * Free, informed and written consent of the minor patient's legal guardians; * Enrolled in the social security system. Exclusion Criteria: 1. Contraindication of MEOPA : * Patients requiring 100% oxygen ventilation * Intracranial hypertension * Altered state of consciousness preventing cooperation * Any condition where air is trapped inside the body and expansion could be dangerous (cranial and/or maxillofacial trauma, pneumothorax, emphysema, gas embolism, following recent scuba diving, decompression sickness following gas encephalography, during middle ear/internal ear or sinus surgery, abdominal gas distension, when air is injected into the epidural space during epidural anesthesia, if the patient has received ophthalmic gas (SF6, C3F8, C2F6) used in eye surgery for as long as the gas bubble persists and up to 3 months afterwards) * Known, unsubstituted vitamin B12 or folic acid deficiency * Recent, unexplained neurological abnormalities 2. Contraindications to induced expectoration : * Clinical instability not conducive to induced expectoration (at practitioner's discretion) * Severe respiratory insufficiency, * Severe spasticity. * Hemoptysis * Decompensated heart failure * Contraindication of hypertonic saline : * Hypersensitivity of the bronchial system to hypertonic sodium chloride solutions. * Hemoptysis * Contraindication to the use of Salbutamol : * Hypersensitivity to any of the constituents of salbutamol-based pressurized or inhaled products. * Intolerance to salbutamol-based pressurized or inhaled products (coughing or bronchospasm occurring immediately after inhalation of the product). * Contraindication of the maneuver performed by the physiotherapist: bullous emphysema, confirmed hiatal or diaphragmatic hernia and rib fragility. 3. Patient with minor parent(s) 4. Uncooperative child 5. Antibiotic therapy administered within the previous 24 hours.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Children are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Brest, University Hospital

    Brest, 29609, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.